Finafloxacin
Based on 1 publication(s) in Google Scholar
Finafloxacin is an orally active fourth-generation fluoroquinolone broad-spectrum antibiotic. Finafloxacin exhibits stronger antibacterial activity in acidic pH environments and is not easily affected by bacterial multidrug efflux transporters. Finafloxacin is effective against a variety of extracellular pathogenic bacteria, and can also accumulate in macrophages, showing excellent antibacterial activity against intracellular Staphylococcus aureus, Listeria monocytogenes, Legionella pneumophila, Burkholderia pseudomallei, and other pathogens. Finafloxacin has been approved by the U.S. FDA for research on acute otitis externa mediated by Pseudomonas aeruginosa. Finafloxacin is also used in studies related to diseases such as melioidosis, inhalational tularemia, and inhalational plague.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.75%
- CAS 番号: 209342-40-5
- 分子式: C20H19FN4O4
- 分子量:398.39
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Finafloxacin
MoreAntibiotic アイソフォーム固有の製品をすべて表示
More
生物活性
|
Quinolone |
Finafloxacin (24 h; 48 h) inhibits growth of extracellular MSSA, CA-MRSA, HA-MRSA, VISA, L. monocytogenes, and L. pneumophila with MICs ranging from 0.01 mg/L (against L. pneumophila) to 16 mg/L (against a ciprofloxacin-resistant HA-MRSA isolate), and shows reduced susceptibility to NorA and Lde efflux mechanisms compared to ciprofloxacin[1].
Finafloxacin is bactericidal against intracellular L. monocytogenes in human THP-1 macrophages at neutral pH, but is less potent than ciprofloxacin[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Finafloxacin (23.1 mg/kg; p.o.; every 8 h; 3-7 days) provides 100% survival when administered starting 24 h post inhalational Y. pestis challenge, and 80% to 100% survival when administered starting 38 h postchallenge[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 8 to 10 weeks old, inhalational challenge with Francisella tularensis SCHU S4)[3]
-
Dosage:23.1 mg/kg
-
Administration:p.o.; every 8 h; 3 days; 7 days
-
Result:Provided 100% survival when treatment initiated at 24 h postchallenge, with 90% of mice showing no clinical signs of disease, no detectable bacteria in organs, and no histopathological changes typical of infection.
Increased time to death significantly compared to ciprofloxacin when treatment initiated at 72 h postchallenge for 3 days, with mice resolving clinical signs by day 7, relapsing by day 11, and succumbing by day 16.
Provided 50% survival when treatment initiated at 72 h postchallenge for 7 days, with all surviving mice having no detectable bacteria in organs and no histopathological changes typical of infection.
Caused less weight loss than ciprofloxacin in the 3-day 72 h postchallenge regimen, with differences identifiable at days 9 to 10 postchallenge.
化学情報
-
CAS 番号 209342-40-5
-
性状 Solid
-
分子量 398.39
-
分子式 C20H19FN4O4
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4C[C@]5([H])OCCN[C@@]5([H])C4)=C3C#N)C1=O)O
-
別名
フィナフロキサシン
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Microb Pathog
Antibiotic discovery against Piscirickettsia salmonis using a combined in silico and in vitro approach. [Abstract]2023 Jul:180:106122. PMID: 37094756
溶剤 & 溶解度
DMSO : 6.4 mg/mL (16.06 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5101 mL | 12.5505 mL | 25.1010 mL | 62.7526 mL |
| 5 mM | 0.5020 mL | 2.5101 mL | 5.0202 mL | 12.5505 mL | |
| 10 mM | 0.2510 mL | 1.2551 mL | 2.5101 mL | 6.2753 mL | |
| 15 mM | 0.1673 mL | 0.8367 mL | 1.6734 mL | 4.1835 mL |
Finafloxacin 関連分類
HY-13451 関連分類
Powered by Bioz